versus 52 (33–67) ng/mL, p = 0.018), while a non-significant trend towards higher plasma PCSK9 levels was detected in pSS patients with low-to-moderate CV risk as compared to those with high-to-very-high CV risk (176 (100–258) versus 73 (39–264) ng/mL, p = 0.060) (Figure 4). This evidence concerns the gene PCSK9 and peeling skin syndrome.